

Occipital nerve stimulation in cluster headache

Lansbergen, C.S.; Vos, C.C. de; Brandt, R.B.; Ferrari, M.D.; Huygen, F.J.P.M.; Fronczek, R.

Citation

Lansbergen, C. S., Vos, C. C. de, Brandt, R. B., Ferrari, M. D., Huygen, F. J. P. M., & Fronczek, R. (2024). Occipital nerve stimulation in cluster headache. *European Journal Of Neurology*, *31*(3). doi:10.1111/ene.16212

Version:Publisher's VersionLicense:Creative Commons CC BY 4.0 licenseDownloaded from:https://hdl.handle.net/1887/4180808

Note: To cite this publication please use the final published version (if applicable).

DOI: 10.1111/ene.16212

LETTER TO THE EDITOR



european journal of neurology

Occipital nerve stimulation in medically intractable chronic cluster headache

Dear Editor,

We read with great interest the recently published European Academy of Neurology (EAN) guidelines for the treatment of cluster headache [1]. We applaud the careful and comprehensive analysis of the various acute and prophylactic treatment options. However, we were surprised by the recommendation to use sphenopalatine ganglion stimulation (SPG) and not occipital neurostimulation (ONS) as last resort prophylactic therapy in medically intractable chronic cluster headache (MICCH).

To our knowledge, SPG is no longer available and is not formally approved in any country for the treatment of cluster headache. Although it is effective in the acute treatment of cluster headache attacks [2, 3], there is no randomized controlled evidence for prophylactic efficacy. A potential preventive effect was observed in an uncontrolled open-label extension study, and suggested in a doubleblind randomized controlled trail on the acute effect of SPG on cluster headache attacks, not the preventive effect [2, 3].

In contrast, ONS was found to be rapidly and long-term (>5 years) prophylactically effective (50% reduction of attack frequency), safe, and well tolerated in the randomised controlled ICON trial [4] and the recently published prospective long-term follow-up L-ICON study [5]. The proportion of satisfied patients was also extremely high (>90%). These positive findings were reaffirmed in a systematic review and meta-analysis also published after the EAN taskforce literature review [6, 7]. ONS is now officially approved and reimbursed in several European countries for the prophylactic treatment of MICCH.

The EAN guideline raised concerns about a poor safety profile of ONS based on studies conducted in the early stages of ONS development [1]. Hardware-related adverse events (e.g., lead migration or battery depletion) did occur in the early phase of the ICON trial. These were mainly due to short battery life and (off-label) suboptimal leads that were originally intended for use in spinal cord stimulation and were less suitable for placement on the back of the head, where more flexibility is required. Recent developments (e.g., improved implantation procedures, better anchored flexible leads better suited for placement at the back of the head, and less need to replace batteries) have significantly reduced the occurrence of such hardware-related adverse events. In the prospective long-term ONS follow-up L-ICON study, these improved techniques resulted in a hardware-related serious adverse event rate of 0.35 per personyear [95% CI 0.28 – 0.41]. No biological complications (e.g., serious wound infection) were reported [5].

ONS also proved to be cost-effective compared to conventional therapy in the treatment of MICCH, with an average lower annual cost of €1344 [8]. This study also observed a significant improvement in quality of life, with a gain of 0.28 quality-adjusted life years. In the Netherlands, we now successfully implant ONS in approximately 60 MICCH patients per year, with hardly any safety or tolerability problems.

In conclusion, SPG has not (yet) been shown to have a prophylactic effect in cluster headache and is no longer available. In contrast, ONS has proven to be an effective, well-tolerated, and safe treatment option for patients with chronic cluster headache who do not respond to standard medical treatment. It is also cost-effective and accepted as reimbursed care by several European countries. Ongoing developments in hardware and implantation procedures ensure ever lower risk of complications. We realize that some of the above information became available only after the EAN task force's literature review and could not be included in the guidelines, yet urge that the EAN guideline be updated accordingly.

AUTHOR CONTRIBUTIONS

Casper S. Lansbergen: Writing – original draft; writing – review and editing. Cecile C. de Vos: Supervision; writing – review and editing. Roemer B. Brandt: Supervision. Michel D. Ferrari: Supervision; writing – original draft; writing – review and editing. Frank J. P. M. Huygen: Supervision. Rolf Fronczek: Writing – review and editing; supervision; conceptualization.

CONFLICT OF INTEREST STATEMENT

None of the authors has any conflict of interest to disclose.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Casper S. Lansbergen¹ Cecile C. de Vos¹ Roemer B. Brandt² Michel D. Ferrari² Frank J. P. M. Huygen¹

Rolf Fronczek² 问

¹Department of Anaesthesiology, Erasmus Medical Center, Rotterdam, the Netherlands ²Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands

Correspondence

Rolf Fronczek, Department of Neurology, Leiden University Medical Centre, Albinusdreef 2, Postbus 9600 RC, Leiden, the Netherlands. Email: r.fronczek@lumc.nl

ORCID

Casper S. Lansbergen [©] https://orcid.org/0009-0004-4822-4895 Cecile C. de Vos [©] https://orcid.org/0000-0001-7210-1693 Roemer B. Brandt [©] https://orcid.org/0000-0002-2932-4872 Michel D. Ferrari [©] https://orcid.org/0000-0001-9691-9449 Frank J. P. M. Huygen [©] https://orcid.org/0000-0002-2852-4880 Rolf Fronczek [©] https://orcid.org/0000-0002-1935-7603

REFERENCES

- May A, Evers S, Goadsby PJ, et al. European academy of neurology guidelines on the treatment of cluster headache. *Eur J Neurol.* 2023;30(10):2955-2979.
- Jurgens TP, Barloese M, May A, et al. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. *Cephalalgia*. 2017;37(5):423-434.
- Goadsby PJ, Sahai-Srivastava S, Kezirian EJ, et al. Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. *Lancet Neurol.* 2019;18(12):1081-1090.
- 4. Wilbrink LA, de Coo IF, Doesborg PGG, et al. Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, doubleblind, multicentre, phase 3, electrical dose-controlled trial. *Lancet Neurol.* 2021;20(7):515-525.
- Brandt RBWL, de Coo IF, Haan J, et al. A prospective open label 2-8 year extension of the randomised controlled ICON trial on the longterm efficacy and safety of occipital nerve stimulation in medically intractable chronic cluster headache. *eBiomedicine*. 2023;98:104895.
- Membrilla JA, Roa J, Diaz-de-Teran J. Preventive treatment of refractory chronic cluster headache: systematic review and metaanalysis. J Neurol. 2023;270(2):689-710.
- 7. Montenegro MM, Kissoon NR. Long term outcomes of occipital nerve stimulation. *Front Pain Res (Lausanne)*. 2023;4:1054764.
- 8. Bulsei J, Leplus A, Donnet A, et al. Occipital nerve stimulation for refractory chronic cluster headache: a cost-effectiveness study. *Neuromodulation*. 2021;24(6):1083-1092.